Unveiling the pulmonary burden of idiopathic inflammatory myopathies in South Africa

Article Sidebar

PDF HTML
Published: 2024-10-14
DOI: https://doi.org/10.7196/AJTCCM.2024.v30i3.2682

Main Article Content

G L Calligaro

Abstract

-

Downloads

Download data is not yet available.

Article Details

Issue

AJTCCM Vol. 30 No. 3

Section

Editorials
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors retain copyright and grant the journal right of first publication.

How to Cite

1.
Calligaro GL. Unveiling the pulmonary burden of idiopathic inflammatory myopathies in South Africa. Afr J Thoracic Crit Care Med [Internet]. 2024 Oct. 14 [cited 2026 Apr. 17];30(3):e2682. Available from: https://samajournals.co.za/index.php/ajtccm/article/view/2682

References

1. Milone M. Diagnosis and management of immune-mediated myopathies. Mayo Clin Proc 2017;92(5):826-837. https://doi.org/10.1016/j.mayocp.2016.12.025

2. Hes T, Wong M, Tikly M, Govind N. Pulmonary manifestations of the idiopathic inflammatory myopathies in a South African population. Afr J Thoracic Crit Care Med 2024;30(3):e1663. https://doi.org/10.7196/AJTCCM.2024.v30i3.1663

3. LongK,DanoffSK.Interstitiallungdiseaseinpolymyositisanddermatomyositis.Clin Chest Med 2019;40(3):561-572. https://doi.org/10.1016/j.ccm.2019.05.004

4. Kiely PD, Chua F. Interstitial lung disease in inflammatory myopathies: Clinical phenotypes and prognosis. Curr Rheumatol Rep 2013;15(9):359. https://doi. org/10.1007/s11926-013-0359-6

5. Cobo-Ibáñez T, López-Longo F-J, Joven B, et al. Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease. Clin Rheumatol 2019;38(3):803-815. https://doi.org/10.1007/s10067- 018-4353-2

6. Vu TTT, Brown KK, Solomon JJ. Myositis-associated interstitial lung disease. Curr Opin Pulm Med 2023;29(5):427-435. https://doi.org/10.1097/MCP.0000000000001000 7. Chang S, Shin MH, Shin JH, Park MS. Clinical characteristics of anti-Jo-1-positive interstitial lung disease. Eur Respir J 2019;54(Suppl 63):PA5183. https://doi.

org/10.1183/13993003.congress-2019.PA5183

8. Ndamase S, Okpechi I, Carrara H, Black J, Calligaro G, Freercks R. Tuberculosis burden in stage 5 chronic kidney disease patients undergoing dialysis therapy at Livingstone Hospital, Port Elizabeth, South Africa. S Afr Med J 2020;110(5):422-426. https://doi.org/10.7196/SAMJ.2020.v110i5.14035

9. Torre-CisnerosJ,DoblasA,AguadoJM,etal.Tuberculosisaftersolid-organtransplant: Incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis 2009;48(12):1657-1665. https://doi.org/10.1086/599035

10. Yuan Z, Chao S, Xu Y, Niu Y. Chemoprophylaxis for the prevention of tuberculosis in kidney transplant recipients: A systematic review and meta-analysis. Front Pharmacol 2023;14:1022579. https://doi.org/10.3389/fphar.2023.1022579